IGHE and asthma: Studies looking at moderate-severe asthma with T2-high inflammation (total IgE ≥100 IU/ml and blood eosinophils ≥140 cells/μl) have shown that treatment with lebrikizumab resulted in 60% reduction of AAER and improved FEV1, but no effect on symptoms (Corren et al., 2011).